A detailed history of Td Asset Management Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 238,212 shares of APLS stock, worth $7.89 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
238,212
Previous 311,832 23.61%
Holding current value
$7.89 Million
Previous $12 Million 42.56%
% of portfolio
0.01%
Previous 0.01%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$28.84 - $41.15 $2.12 Million - $3.03 Million
-73,620 Reduced 23.61%
238,212 $6.87 Million
Q2 2024

Aug 02, 2024

SELL
$38.07 - $59.71 $5.62 Million - $8.81 Million
-147,570 Reduced 32.12%
311,832 $12 Million
Q1 2024

May 08, 2024

SELL
$55.39 - $72.47 $1.32 Million - $1.73 Million
-23,920 Reduced 4.95%
459,402 $27 Million
Q4 2023

Feb 12, 2024

BUY
$37.14 - $64.82 $4.18 Million - $7.29 Million
112,465 Added 30.33%
483,322 $28.9 Million
Q3 2023

Oct 27, 2023

SELL
$23.65 - $89.22 $2.55 Million - $9.62 Million
-107,869 Reduced 22.53%
370,857 $14.1 Million
Q2 2023

Aug 09, 2023

BUY
$76.68 - $93.31 $7.73 Million - $9.4 Million
100,758 Added 26.66%
478,726 $43.6 Million
Q1 2023

May 10, 2023

BUY
$46.59 - $66.96 $4.95 Million - $7.12 Million
106,348 Added 39.15%
377,968 $24.9 Million
Q4 2022

Feb 06, 2023

SELL
$43.24 - $61.04 $306,831 - $433,139
-7,096 Reduced 2.55%
271,620 $14 Million
Q3 2022

Nov 07, 2022

BUY
$44.76 - $69.66 $179 - $278
4 Added 0.0%
278,716 $18.2 Million
Q2 2022

Aug 04, 2022

BUY
$35.07 - $59.21 $1.09 Million - $1.84 Million
31,026 Added 12.53%
278,712 $12.6 Million
Q1 2022

May 10, 2022

BUY
$35.46 - $54.12 $3.07 Million - $4.69 Million
86,641 Added 53.8%
247,686 $12.6 Million
Q4 2021

Feb 10, 2022

BUY
$30.74 - $49.16 $1.27 Million - $2.03 Million
41,381 Added 34.58%
161,045 $7.61 Million
Q3 2021

Nov 09, 2021

SELL
$31.4 - $69.84 $619,773 - $1.38 Million
-19,738 Reduced 14.16%
119,664 $3.94 Million
Q2 2021

Aug 11, 2021

BUY
$40.9 - $64.9 $1.5 Million - $2.39 Million
36,779 Added 35.84%
139,402 $8.92 Million
Q1 2021

May 14, 2021

BUY
$40.8 - $57.39 $1.07 Million - $1.5 Million
26,180 Added 34.25%
102,623 $4.4 Million
Q4 2020

Feb 16, 2021

BUY
$30.79 - $57.2 $298,663 - $554,840
9,700 Added 14.53%
76,443 $4.37 Million
Q2 2020

Aug 13, 2020

BUY
$24.8 - $38.49 $880,400 - $1.37 Million
35,500 Added 113.63%
66,743 $2.18 Million
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $151,840 - $375,829
8,478 Added 37.24%
31,243 $837,000
Q3 2019

Nov 07, 2019

BUY
$24.09 - $32.18 $140,300 - $187,416
5,824 Added 34.38%
22,765 $548,000
Q1 2019

May 08, 2019

SELL
$12.81 - $19.82 $37,149 - $57,478
-2,900 Reduced 14.62%
16,941 $330,000
Q4 2018

Feb 01, 2019

BUY
$11.47 - $18.71 $4,588 - $7,484
400 Added 2.06%
19,841 $262,000
Q2 2018

Jul 31, 2018

BUY
$19.63 - $30.0 $381,626 - $583,230
19,441 New
19,441 $428,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.